A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the <scp>FDA</scp> Adverse Event Reporting System Database

20260 citationsJournal Articlegold Open Access

Authors

Boyi Liu · Changsha Medical University

W Zhang · Changsha Medical University

Ruizhe Huang · Changsha Medical University

Dinwen Liu · Changsha Medical University

Jianfeng Liu · University of South China

Ao Han · Changsha Medical University

Yanru Li ·

Abstract

The combination exhibits distinct early-onset toxicities (early-onset hematological/endocrine/hepatic) and novel risks (neuropathy/myocarditis/leukemia), necessitating enhanced initial monitoring and subgroup-specific management.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Pharmacovigilance and Adverse Drug Reactions Lung Cancer Research Studies

Publication Details

Published in: Cancer Medicine

Volume 15, Issue 4, pp. e71527-e71527

DOI: 10.1002/cam4.71527

Field-Weighted Citation Impact: 0.00

Command Palette

A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the <scp>FDA</scp> Adverse Event Reporting System Database

Authors

Abstract

Topics & Keywords

Publication Details